News
VOR
23.67
-0.13%
-0.03
Weekly Report: what happened at VOR last week (0727-0731)?
Weekly Report · 08/03 09:08
Weekly Report: what happened at VOR last week (0720-0724)?
Weekly Report · 07/27 09:08
Vor Biopharma (VOR) Stock May Already Look Fully Priced On Pipeline Hopes
Simply Wall St · 07/25 06:20
Top Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filing
NASDAQ · 07/22 03:20
Weekly Report: what happened at VOR last week (0713-0717)?
Weekly Report · 07/20 09:08
Can Vor Biopharma’s (VOR) New Board Appointment Reshape Its Late-Stage Commercialization Strategy?
Simply Wall St · 07/16 20:35
Weekly Report: what happened at VOR last week (0706-0710)?
Weekly Report · 07/13 09:08
Vor Biopharma Adds Industry Veteran David Zaccardelli to Board
TipRanks · 07/07 20:31
*Vor Biopharma: Andrew Levin Has Stepped Down From the Board
Dow Jones · 07/07 20:03
Press Release: Vor Bio Appoints David Zaccardelli to Board of Directors
Dow Jones · 07/07 20:01
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
Seeking Alpha · 07/07 18:39
Weekly Report: what happened at VOR last week (0629-0703)?
Weekly Report · 07/06 09:08
Why Vor Biopharma (VOR) Is Up 27.9% After Broad Russell Index Inclusion And What's Next
Simply Wall St · 07/05 20:18
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday
Benzinga · 07/02 14:24
3 Reasons Vor Biopharma (VOR) Looks Pricey On Russell Index Inclusion
Simply Wall St · 06/30 21:12
Weekly Report: what happened at VOR last week (0622-0626)?
Weekly Report · 06/29 09:08
Weekly Report: what happened at VOR last week (0615-0619)?
Weekly Report · 06/22 09:09
Weekly Report: what happened at VOR last week (0608-0612)?
Weekly Report · 06/15 09:09
Vor Biopharma shareholders back directors and governance measures
TipRanks · 06/12 20:39
Weekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data
NASDAQ · 06/12 15:36
More
Webull provides a variety of real-time VOR stock news. You can receive the latest news about Vor Biopharma Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.